ETF name(Code), Benchmark Index, Inception date, creation unit, Net Asset (KRW 0.1 billion), Trustee, Rule of Dividend payment, Market Price per share (KRW), iNAV per share (KRW), trading volume (share), Total Expense ratio table
ETF Name (code)
Benchmark Index
Inception date
Creation Unit
AUM (KRW)
KB RISE HealthCare Fixed Income Balanced ETF
(253290)
FnGuide HealthCare Mix Index
2016.09.23
200,000
14,509,379,055
Trustee
Market Price per share (KRW)
NAV
Trading Volume (shares)
하나은행
12,085
※ t-1 last price
12,091
11,293
authorized participant, Liquidity provider table
Total Expense Ratio
Distribution Frequency
Year 0.35%
(Designated participating company : 0.001%,
Collective investment : 0.309%,
trust : 0.02%,
General affairs : 0.02%)
Based on the business day before the interest payment date of the stocks constituting the index in June and December (occasional payment)
The FnGuide Healthcare Balanced Index is an index consisting of stock items constituting the FnGuide Healthcare Index and three KTBs constituting the MKF 3-year KTB Index. It maintains a 7:3 ratio of bonds to stocks everyday.
Name, Ticker, Number. of shares, Weight(%), market price (KRW)
No. (Number)
Name
Ticker
Number of shares
Weight(%)
Market price (KRW)
1
KTB03000-2909(24-7)
KR103501GE98
666,666,666
27.88
682,577,999
2
KTB02875-2712(24-12)
KR103501GEC6
500,000,000
20.63
505,102,000
3
RISE HealthCare
KR7253280002
20,641
12.2
298,572,065
4
RISE KTB
KR7114100001
1,900
8.52
208,496,500
5
KTB03250-2706(24-4)
KR103501GE64
166,666,667
6.92
169,313,167
6
원화예금
KRD010010001
104,451,976
4.27
104,451,976
7
F 202506
KR4165W60005
0.67
2.92
71,446,702
8
Alteogen
KR7196170005
142
2.38
58,291,000
9
SAMSUNG BIOLOGICS
KR7207940008
46
1.93
47,334,000
10
Celltrion
KR7068270008
261
1.75
42,777,900
11
Yuhan
KR7000100008
378
1.67
40,975,200
12
HLB
KR7028300002
629
1.37
33,588,600
13
PharmaResearch
KR7214450009
55
1.18
28,765,000
14
SKBP
KR7326030004
242
0.92
22,627,000
15
SCD
KR7000250001
124
0.86
20,956,000
16
HanmiPharm
KR7128940004
56
0.72
17,584,000
17
SKBS
KR7302440003
235
0.45
11,056,750
18
CLASSYS
KR7214150005
155
0.39
9,517,000
19
SEEGENE
KR7096530001
284
0.39
9,485,600
20
ST Pharm
KR7237690003
112
0.38
9,296,000
21
Celltrionph
KR7068760008
178
0.37
9,060,200
22
HANALL BIOPHARMA
KR7009420001
313
0.35
8,513,600
23
MedyTox
KR7086900008
48
0.33
8,126,400
24
Hanmi Science
KR7008930000
180
0.29
7,011,000
25
GC Corp
KR7006280002
49
0.27
6,688,500
26
DAEWOONG PHARM
KR7069620003
40
0.27
6,500,000
27
CHONGKUNDANG
KR7185750007
76
0.27
6,688,000
28
HK inno.N
KR7195940002
126
0.23
5,670,000
29
Pharmicell
KR7005690003
496
0.23
5,713,920
30
CHA Biotech
KR7085660009
473
0.21
5,259,760
31
Daewoong
KR7003090008
174
0.19
4,645,800
32
HLBPHARMA
KR7047920004
240
0.19
4,610,400
33
Binex
KR7053030003
255
0.18
4,429,350
34
DENTIUM
KR7145720009
58
0.16
4,019,400
35
WONTECH
KR7336570007
381
0.16
4,038,600
36
EuBio
KR7206650004
275
0.15
3,550,250
37
SD Biosensor
KR7137310009
316
0.15
3,728,800
38
DongKook Pharm
KR7086450004
206
0.15
3,687,400
39
SELVAS AI
KR7108860008
210
0.13
3,276,000
40
i-SENS
KR7099190001
186
0.13
3,135,960
41
BIONEER
KR7064550007
197
0.13
3,195,340
42
Boryung
KR7003850005
331
0.12
2,949,210
43
JWPHARMA
KR7001060003
118
0.12
2,832,000
44
BioPlus
KR7099430001
352
0.11
2,590,720
45
T&L
KR7340570001
41
0.11
2,587,100
46
Donga ST
KR7170900005
43
0.09
2,109,150
47
GC CELL
KR7144510005
70
0.06
1,554,000
48
Aprogen
KR7007460009
1,324
0.04
951,956
Investment notice
- The information provided on this website is based on reliable sources, but its accuracy and completeness are not guaranteed.
- Financial investment products are not protected by the Korea Deposit Insurance Corporation in accordance with the Depositor Protection Act, and a loss of investment principal may occur, which belongs to the investor.
- Past performance does not guarantee future profits.
- In the case of a collective investment scheme that invests in foreign securities, asset values may be lost due to risks caused by market, political, and economic conditions in the target country.
- Derivatives may lose all or a significant portion of the investment principal in a short period of time due to high price volatility, and there is a risk that the counterparty may not be able to fulfill the terms of the contract when investing in over-the-counter derivatives.
- Before investing, be sure to read the investment prospectus and contract recommendation document regarding the investment subject, redemption method, and fee.